Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risk

Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risks in Alabama Population

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03040492

Enrollment

200

Registered

2017-02-02

Start date

2012-10-31

Completion date

2017-06-30

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Cancer, Non-Melanoma

Brief summary

Detailed description

The purpose of this study is to discover whether certain Vitamin D Receptor (VDR) gene polymorphisms are associated with an increased risk of cutaneous basal cell carcinoma (BCC) and/or cutaneous squamous cell carcinoma (SCC) in an Alabama population. Participant demographic information such as physical characteristics (e.g., ethnicity), family history, and cancer diagnosis will be collected in order to determine if there are relationships between the gene polymorphisms, cancer diagnosis, and these characteristics. By identifying the VDR polymorphisms for the Apa1, Taq1, Bsm1, and Fok1 genes within the participant population and comparing the genotypes to controls, the investigators hope to demonstrate which gene polymorphisms indicate an increased risk for SCC or BCC. Inclusion- patients with a non-melanoma skin cancer. Participants must be 50 years old or older. Controls- patients without non-melanoma skin cancer and who have no family history of skin cancer. They must also be 50 years old or older; Inclusion for both groups- English speakers and patients at the Kirklin Clinic during the months of our data collection. Exclusion criteria will be patients younger than 50 years old or who have a diagnosis of melanoma or other type of cancer, or who are non-English speakers.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients with non-melanoma skin cancer (cases) * Patients without non-melanoma skin cancer or history of non-melanoma skin cancer (controls) * Age 50 and older * Native English speakers * Patients at Kirklin Clinic

Exclusion criteria

* Age less than 50 * Diagnosis of melanoma or other type of cancer * Non-English speakers

Design outcomes

Primary

Measure	Time frame	Description
SIngle nucleotide polymorphisms (SNP)	2 years	Number of patients with the presence or absence of VDR SNP in their DNA isolated from their blood samples. PCR will be performed on the DNA samples for using specific primers for SNP, and the PCR products will be sequenced for detection of SNP.

Countries

United States

Outcome results